Faculty of Medical Sciences, University of Buenos Aires

ATCC Appoints Dr. Alfredo Molinolo to Its Board of Directors

Retrieved on: 
Thursday, November 2, 2023
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Genetics, Moores Cancer Center, Biorepository, DVM, Faculty of Medical Sciences, University of Buenos Aires, Head, Publication, Doctor of Philosophy, National Institute of Dental and Craniofacial Research, Hospital Rivadavia, HNSCC, Mouse Models of Human Cancer database, Medicine, Breast cancer, Medical research, University, University of California, San Diego, Collection, Breast, Bangladesh Technical Education Board, Neck, Management, Pathology, ATCC, MD, Biology, Cancer

“Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.

Key Points: 
  • “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
  • Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
  • Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
  • “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

Retrieved on: 
Wednesday, July 19, 2023
Nucleus, GSK plc, Amgen, Medical Affairs Bureau, University, Senior, ALL, Belimumab, Bone marrow, Wharton School of the University of Pennsylvania, Trastuzumab/hyaluronidase, Roche, Haemophilia, Human Genome Sciences, MBA, SLE, AstraZeneca, Bachelor of Science, Veronica, ASCO, Faculty of Medical Sciences, University of Buenos Aires, CDMO, Acquisition, Project management, Partner, Patient, Regeneron Pharmaceuticals, Engineering, Moderna, Hematology, CFO, SVP, Trastuzumab emtansine, Therapy, Stomach, BLA, HGS, Ionis Pharmaceuticals, Management, Pharmaceutical industry, West Virginia University

LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert F. Dolski as Chief Financial Officer (CFO), effective August 7, 2023.

Key Points: 
  • Mr. Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as Chief Financial Officer at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. in 2022.
  • Mr. Dolski will succeed Dr. Lucinda Crabtree, who, as previously announced, will be leaving Autolus in August.
  • Veronica joined Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer.
  • Veronica joins Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer.

Versameb Strengthens its Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.

Versameb Strengthens its Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
SPAC, Urinary incontinence, Faculty, Ferring Pharmaceuticals, Medical Affairs Bureau, Drug development, Pediatrics, University, Therapy, Gastroenterology, Ipsen, Roche, Infection, SUI, Faculty (division), MBA, RNA, Doctor of Philosophy, Faculty of Medical Sciences, University of Buenos Aires, Sarepta Therapeutics, M.D, Regeneration, Novartis, MD, European, CPA, CFO, Knowledge, Growth, Paris Diderot University, Obstetrics, IND, Paris Descartes University, Imperial College London, Brevan Howard, BLA, Medical device, Pharmaceutical industry, Management, Economics

The appointments come at a significant time of growth and expansion for Versameb.

Key Points: 
  • The appointments come at a significant time of growth and expansion for Versameb.
  • Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: "The experience of Hernán, Lily, Paul and Alexandre significantly strengthens the board of directors as we advance our lead candidate, VMB-100 for the treatment of SUI, into clinical development and further expand our technology platform, Versagile, with the development of two new discovery programs.
  • He is a member of the scientific advisory team for Laidlaw Venture Partners and serves on the Board of Directors for Voltron Therapeutics.
  • Versameb has developed a groundbreaking, proprietary technology platform, VERSagile, which optimizes the application of functional RNA in different disease contexts.